Published in Neurology on May 01, 1993
Cyclophosphamide therapy in pediatric multiple sclerosis. Neurology (2009) 1.62
Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry (1997) 1.44
Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J Clin Invest (1998) 1.36
Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry (2004) 1.24
Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch Neurol (2008) 1.10
Role of steroids and immunosuppression and effects of interferon beta-1b in multiple sclerosis. West J Med (1994) 0.89
Systematic review of immunomodulatory drugs for the treatment of people with multiple sclerosis: Is there good quality evidence on effectiveness and cost? J Neurol Neurosurg Psychiatry (2001) 0.87
Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms. Ther Adv Neurol Disord (2009) 0.85
Multiple Sclerosis: Immunotherapy. Curr Treat Options Neurol (1999) 0.85
Chemotherapeutics in the treatment of multiple sclerosis. Ther Adv Neurol Disord (2010) 0.85
Escalating immunotherapy of multiple sclerosis. Ther Adv Neurol Disord (2008) 0.84
Pediatric multiple sclerosis. NeuroRx (2006) 0.84
The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients-- twenty-four months follow-up. J Neurol (2005) 0.81
Lights and shadows of cyclophosphamide in the treatment of multiple sclerosis. Autoimmune Dis (2011) 0.81
Disease-modifying Therapies for Multiple Sclerosis. Curr Treat Options Neurol (2003) 0.81
Role of immunosuppressive therapy for the treatment of multiple sclerosis. Neurotherapeutics (2013) 0.81
Immunotherapy for multiple sclerosis. J Neurol Neurosurg Psychiatry (1994) 0.80
Mitoxantrone versus cyclophosphamide in secondary-progressive multiple sclerosis: a comparative study. J Neurol (2006) 0.80
Disease-modifying therapy of pediatric multiple sclerosis. Neurotherapeutics (2013) 0.77
Diagnosis and treatment of multiple sclerosis in pediatric and adolescent patients: current status and future therapies. Adolesc Health Med Ther (2010) 0.77
Cyclophosphamide and MS. Neurology (1994) 0.76
Immunosuppression in clinical practice: approaches to individualized therapy. J Neurol (2008) 0.75
Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis. PLoS One (2017) 0.75
Neurology. BMJ (1994) 0.75
Diagnosis and Management of Multiple Sclerosis in Children. Iran J Child Neurol (2016) 0.75
Incidence and types of adverse events and negligent care in Utah and Colorado. Med Care (2000) 13.46
CD4+CD25high regulatory cells in human peripheral blood. J Immunol (2001) 11.25
Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science (1994) 8.69
Impact of language barriers on patient satisfaction in an emergency department. J Gen Intern Med (1999) 5.35
Using a computerized sign-out program to improve continuity of inpatient care and prevent adverse events. Jt Comm J Qual Improv (1998) 4.92
Epidemiology of sepsis syndrome in 8 academic medical centers. JAMA (1997) 4.49
T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature (1990) 4.40
Quality of life and clinical outcomes in elderly patients treated with ventricular pacing as compared with dual-chamber pacing. Pacemaker Selection in the Elderly Investigators. N Engl J Med (1998) 4.22
Extreme Th1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes. Nature (1998) 4.10
Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol (1994) 4.07
Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med (1995) 4.03
Causes of death in homeless adults in Boston. Ann Intern Med (1997) 3.71
Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology (2008) 3.68
Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med (1999) 3.66
Effects of oral administration of type II collagen on rheumatoid arthritis. Science (1993) 3.32
The effect of kaolin on immunoglobulins: an improved technique to remove the nonspecific serum inhibitor of reovirus hemagglutination. J Immunol (1967) 3.17
A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. The Multiple Sclerosis Genetics Group. Nat Genet (1996) 2.98
A simple method for DNA purification from peripheral blood. Anal Biochem (1988) 2.98
Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science (1993) 2.97
Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med (1983) 2.93
The efficacy of preemployment drug screening for marijuana and cocaine in predicting employment outcome. JAMA (1990) 2.89
Shared human T cell receptor V beta usage to immunodominant regions of myelin basic protein. Science (1990) 2.86
The "To Err is Human" report and the patient safety literature. Qual Saf Health Care (2006) 2.67
The comparative enzymology of creatine kinases. I. Isolation and characterization from chicken and rabbit tissues. J Biol Chem (1967) 2.54
Negligent care and malpractice claiming behavior in Utah and Colorado. Med Care (2000) 2.51
Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology (2004) 2.50
Determinants of patient satisfaction and willingness to return with emergency care. Ann Emerg Med (2000) 2.49
Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med (1994) 2.45
Disease steps in multiple sclerosis: a simple approach to evaluate disease progression. Neurology (1995) 2.42
Integrating risk factors: HLA-DRB1*1501 and Epstein-Barr virus in multiple sclerosis. Neurology (2008) 2.41
Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones. J Exp Med (1994) 2.37
Disease steps in multiple sclerosis: a longitudinal study comparing disease steps and EDSS to evaluate disease progression. Mult Scler (1999) 2.35
Late complications of immune deviation therapy in a nonhuman primate. Science (1996) 2.30
HLA B*44: protective effects in MS susceptibility and MRI outcome measures. Neurology (2010) 2.29
Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J Exp Med (1995) 2.28
Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. J Clin Invest (1996) 2.27
In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. N Engl J Med (1985) 2.27
Loss of suppressor T cells in active multiple sclerosis. Analysis with monoclonal antibodies. N Engl J Med (1980) 2.21
Demyelinative myelopathy in mice induced by the DA virus. J Neurol Sci (1976) 2.20
Risk factors for death in homeless adults in Boston. Arch Intern Med (1998) 2.13
Performance of generalized estimating equations in practical situations. Biometrics (1994) 2.12
The relationship of postoperative delirium with psychoactive medications. JAMA (1994) 2.09
Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions. Ann Neurol (1986) 2.06
Cardiac dysfunction and mortality in HIV-infected children: The Prospective P2C2 HIV Multicenter Study. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group. Circulation (2000) 2.04
Supraventricular arrhythmia in patients having noncardiac surgery: clinical correlates and effect on length of stay. Ann Intern Med (1998) 2.04
HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Hum Genet (2003) 2.02
Does the computerized display of charges affect inpatient ancillary test utilization? Arch Intern Med (1997) 2.01
Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest (2000) 2.00
T-cell recognition of myelin basic protein. Immunol Today (1991) 1.98
Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci U S A (1997) 1.95
The association of physician attitudes about uncertainty and risk taking with resource use in a Medicare HMO. Med Decis Making (1998) 1.93
Improved visual function and attenuation of declines in health-related quality of life after cataract extraction. Arch Ophthalmol (1994) 1.93
The association of intraoperative factors with the development of postoperative delirium. Am J Med (1998) 1.92
Cardiac structure and function in children with human immunodeficiency virus infection treated with zidovudine. N Engl J Med (1992) 1.92
CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation. Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production. J Immunol (1992) 1.91
Gamma delta T-cell receptor repertoire in acute multiple sclerosis lesions. Proc Natl Acad Sci U S A (1992) 1.88
Absence of cardiac toxicity of zidovudine in infants. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection Study Group. N Engl J Med (2000) 1.87
Influence of age-related maculopathy on visual functioning and health-related quality of life. Am J Ophthalmol (1999) 1.86
Common T-cell receptor V beta usage in oligoclonal T lymphocytes derived from cerebrospinal fluid and blood of patients with multiple sclerosis. Ann Neurol (1991) 1.85
Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand. Immunity (1995) 1.83
Expansion of autoreactive T cells in multiple sclerosis is independent of exogenous B7 costimulation. J Immunol (1998) 1.82
T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol (1995) 1.78
Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for antigen-specific antibody mediation. Ann Neurol (1999) 1.77
Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis. Neurology (1989) 1.77
Treatment of uveitis by oral administration of retinal antigens: results of a phase I/II randomized masked trial. Am J Ophthalmol (1997) 1.71
A follow-up study of morbidity and mortality associated with hepatitis C virus infection and its interaction with human T lymphotropic virus type I in Miyazaki, Japan. J Infect Dis (2000) 1.71
Nonurgent emergency department visits: the effect of having a regular doctor. Med Care (1998) 1.70
Correlation between CAG repeat length and clinical features in Machado-Joseph disease. Am J Hum Genet (1995) 1.67
Design and implementation of the North American Pediatric Cardiomyopathy Registry. Am Heart J (2000) 1.65
Cardiac morbidity and related mortality in children with HIV infection. JAMA (1993) 1.65
Seminars in medicine of the Beth Israel Hospital, Boston. Pathogenesis of diseases induced by human lymphotropic virus type I infection. N Engl J Med (1993) 1.64
Linkage of the MHC to familial multiple sclerosis suggests genetic heterogeneity. The Multiple Sclerosis Genetics Group. Hum Mol Genet (1998) 1.63
A susceptibility locus for multiple sclerosis is linked to the T cell receptor beta chain complex. Cell (1989) 1.63
Distinct molecular forms of human T cell receptor gamma/delta detected on viable T cells by a monoclonal antibody. J Exp Med (1988) 1.62
Differential display cloning of a novel human histone deacetylase (HDAC3) cDNA from PHA-activated immune cells. Biochem Biophys Res Commun (1998) 1.62
Direct enumeration of Borrelia-reactive CD4 T cells ex vivo by using MHC class II tetramers. Proc Natl Acad Sci U S A (2000) 1.61
Reliability of multicenter pediatric echocardiographic measurements of left ventricular structure and function: the prospective P(2)C(2) HIV study. Circulation (2001) 1.61
Patient satisfaction in the ambulatory setting. Influence of data collection methods and sociodemographic factors. J Gen Intern Med (1996) 1.58
Age-related differences in management of heart disease: a study of cardiac medication use in an older cohort. Pacemaker Selection in the Elderly (PASE) Investigators. J Am Geriatr Soc (1999) 1.58
Clonal expansion and persistence of human T cells specific for an immunodominant myelin basic protein peptide. J Immunol (1994) 1.58
Multifactor dimensionality reduction reveals gene-gene interactions associated with multiple sclerosis susceptibility in African Americans. Genes Immun (2006) 1.56
The neuroimmunology of multiple sclerosis: possible roles of T and B lymphocytes in immunopathogenesis. J Clin Immunol (2001) 1.56
Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate. J Clin Invest (1995) 1.54
American Academy of Neurology qualifications and guidelines for the physician expert witness. Neurology (2006) 1.54
The role of prolactin in autoimmune demyelination: suppression of experimental allergic encephalomyelitis by bromocriptine. Ann Neurol (1991) 1.53
Identification of a T cell subset capable of both IFN-gamma and IL-10 secretion in patients with chronic Borrelia burgdorferi infection. J Immunol (1998) 1.53
Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet (1999) 1.53
Direct analysis of viral-specific CD8+ T cells with soluble HLA-A2/Tax11-19 tetramer complexes in patients with human T cell lymphotropic virus-associated myelopathy. J Immunol (1999) 1.51
The role of the Toll receptor pathway in susceptibility to inflammatory bowel diseases. Genes Immun (2007) 1.50
Hospital ownership and preventable adverse events. Int J Health Serv (2000) 1.50
CNS involvement in the non-Hodgkin's lymphomas. Cancer (1980) 1.49
Triage decisions for emergency department patients with chest pain: do physicians' risk attitudes make the difference? J Gen Intern Med (1995) 1.49